Evaluating the efficacy and safety of neonatal chyme reinfusion therapy: A feasibility study using a novel medical device.

Autor: Ludlow E; Te Whatu Ora Counties Manukau, New Zealand; Department of Surgery, The University of Auckland, New Zealand; The Insides Company, New Zealand., Harrington T; The Insides Company, New Zealand; Te Whatu Ora Te Toka Tumai Auckland, New Zealand., Davidson R; The Insides Company, New Zealand., Davidson J; The Insides Company, New Zealand., Aikins K; Te Whatu Ora Te Toka Tumai Auckland, New Zealand., O'Grady G; Department of Surgery, The University of Auckland, New Zealand; The Insides Company, New Zealand., Bissett I; Department of Surgery, The University of Auckland, New Zealand; The Insides Company, New Zealand. Electronic address: i.bissett@auckland.ac.nz.
Jazyk: angličtina
Zdroj: Clinical nutrition (Edinburgh, Scotland) [Clin Nutr] 2024 Oct; Vol. 43 (10), pp. 2253-2260. Date of Electronic Publication: 2024 Aug 21.
DOI: 10.1016/j.clnu.2024.08.016
Abstrakt: Objectives: Neonatal and pediatric intestinal failure related to enterostomy is an infrequent but burdensome condition associated with substantial morbidity and mortality. This study presents the development and clinical validation of a novel device to resolve these problems, by formalizing a safe and efficient enterostomy chyme reinfusion technique.
Methods: A novel neonatal chyme reinfusion device was designed and manufactured ('The Insides Neo', The Insides Company, New Zealand), prior to validation in a feasibility study in tertiary neonatal intensive care centres. Neonates with double enterostomy were recruited and commenced on chyme reinfusion therapy using the novel device to test safety, efficacy, tolerability, and usability within nursing workflows. Device and clinical outcomes were recorded along with nursing feedback. Registered under the ANZCTR, identifier no. ACTRN12621000835842p.
Results: Ten neonates were recruited across two centres, with a median usage duration of 37.5 (range 12-84) days. Following initiation of therapy, rate of weight gain increased from mean 68.8 ± 37.4 to 197 ± 25.0 g/week (p = 0.024). Of the 7/10 neonates on PN at commencement of therapy, 4/7 were able to wean and achieve enteral autonomy. All neonates tolerated the device with uniformly positive nursing feedback and minimal time to learn and incorporate the novel device into nursing workflows. There were no device-related adverse events.
Conclusions: A novel device was developed and validated to be safe and effective at performing chyme reinfusion therapy in neonates. This device is anticipated to improve the clinical care and outcomes of neonatal patients with double enterostomies.
Competing Interests: Conflict of interest E. Ludlow is an employee and shareholder in The Insides Company. T. Harrington contracts to The Insides Company. R. Davidson, J. Davidson, G. O'Grady, and I. Bissett are Founders of The Insides Company.
(Copyright © 2024 The Author(s). Published by Elsevier Ltd.. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: